NEJM -- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Links shared publicly online about this topic.
- 1,711total visits
NEJM -- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Original Article from The New England Journal of Medicine -- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
View full resource at content.nejm.org
Tags: Parkinson's Disease, Disease and Condition
Most Recently Shared on September 30, 2009 at 6:08 pm By:
ADAGIO -2 yr f/u for rasagiline in NEJM. Neuroprotection in PD? You look @ data and decide http://bit.ly/3Gipsc #neuroclerk
ScienceDirect - The Lancet Neurology : A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
sciencedirect.com — “ScienceDirect - The Lancet Neurology : A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes” View full resource at sciencedirect.com
Most Recently Shared on April 16, 2011 at 9:01 am By:
Analysis of the results of the ADAGIO study will inform us of future clinical trial design. http://t.co/NEyDoKq
Advertisement
